Samsung Biologics Unveils Accelerated Platform Service for Contract Development of Pharmaceuticals

From Cell Line Development to IND Application in as Fast as 9 Months

Samsung Biologics announced 'S-Cellerate' at the 'Bio Process International' held in Boston, USA, from the 20th to the 23rd of this month. (Photo by Samsung Biologics)

[Asia Economy Reporter Kim Ji-hee] Samsung Biologics announced on the 22nd that it has unveiled the pharmaceutical contract development (CDO) platform 'S-Cellerate,' which drastically shortens the time required from cell line development to Investigational New Drug (IND) application submission, process characterization (PC), and Biologics License Application (BLA) submission. Using this platform, the period from cell line development to IND application can be as short as 9 months.

Samsung Biologics officially announced S-Cellerate at the 'Bio Process International (BPI)' event held over three days from the 20th to the 23rd. The event was conducted in a hybrid format combining an offline exhibition at the Boston Convention Center in the United States and an online exhibition.

S-Cellerate is a foundational technology platform that standardizes and rapidly supports the services required for biopharmaceutical development. It consists of two services: the 'S-Cellerate to IND' platform service and the 'S-Cellerate to BLA' platform service.

The S-Cellerate to IND platform service supports everything from initial cell line development to production process and analytical method development, nonclinical and clinical material production, and IND application. Through optimized and standardized processes at each development stage, the time from cell line development to IND application has been shortened to as little as 9 months. The S-Cellerate to BLA service is a platform service that covers the late development stages, including PC and process performance qualification (PPQ), leading up to the BLA for commercial sales.

Since entering the pharmaceutical contract development service in 2018, Samsung Biologics has secured 81 contracts through the second quarter of this year. The core competitive advantage lies in the 'one-stop' service that allows biopharmaceutical companies to handle everything from candidate material discovery to clinical sample production and large-scale commercial manufacturing in one place, thereby reducing time and costs.

John Rim, CEO of Samsung Biologics, said, "Through our contract development services built on abundant experience, data, and expertise, our clients can drastically shorten the development period for biopharmaceuticals and reduce the total cost of ownership (TCO) invested in research and development. We will continue to innovate our services to achieve the highest customer satisfaction in line with the changing market and to enable groundbreaking biopharmaceuticals to enter the market more quickly."

This content was produced with the assistance of AI translation services.